nightclaude · nightly deep dive · 2026-10-28

HIV annuity funds oncology optionality, but $159.08 prices perfection

At $159.08, just under the $160.51 52 week high, Gilead Sciences commands a $197.25B market capitalization and $218.53B enterprise value on FY2025 SEC revenue of $29.44B and operating income of $10.02B. With a 79.6% gross margin, $10.02B in operating cash flow and a $4.00B dividend funded from $9.46B in free cash flow, the HIV annuity built on Biktarvy, Sunlenca and Yeztugo trades at 16.05 times forward earnings against ViiV, a price that leaves no room for payer or patent error.

Gilead cures its best customers, then bills its most loyal ones for life. That is the paradox of a Foster City antiviral house with 17000 employees that turned HIV treatment with Biktarvy, Descovy, Sunlenca and Yeztugo into FY2025 SEC revenue of $29.44B at 79.6% gross margin and $10.02B of operating income, then watched net income snap from $480.00M in FY2024 to $8.51B in FY2025 while operating cash flow held at $10.02B. Unlike Merck or Johnson and Johnson, which can hide a miss behind breadth, Gilead lives on adherence, where switching costs defend Biktarvy against ViiV Healthcare while curative Epclusa shrinks its own hepatitis C pool and Trodelvy chases AstraZeneca and Daiichi in antibody drug conjugates.

At $159.08, up 35.3% in one year and 182.3% in five years from $48.96, the market no longer treats Gilead as a $24.94B debt laden legacy paying $4.00B in dividends and $1.92B in buybacks from $7.56B in cash. It prices 10.2% revenue growth, $13.58B in EBITDA and a $160.19 mean target at 16.05 times forward earnings and 14.97 times EV to EBITDA as if the Sunlenca and Yeztugo prevention franchise extends the annuity forever.

History & Ownership

Gilead Sciences, Inc. was incorporated in 1987 and is headquartered in Foster City, California, where it has grown from an antiviral startup into a 17,000 employee biopharma with a market capitalization of $197.25B and enterprise value of $218.53B at a share price of $159.08. The origin story is HIV and antivirals, then serial expansion by acquisition and internal virology into liver disease, COVID-19, oncology and cell therapy. Unlike a founder controlled biotech, Gilead is a mature, widely held Nasdaq compounder built around the Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza and Yeztugo HIV franchise, plus Epclusa, Livdelzi and Vemlidy in liver disease, Yescarta and Tecartus in CAR T, Trodelvy in breast and other solid tumors, AmBisome and Veklury.

From HIV Annuity To Diversified Franchise

Gilead never had a spin off overhang in the modern period. It listed decades ago and compounded as a public currency acquirer, a model closer to Amgen and Merck than to a venture backed single asset biotech. The economic signature is a patented HIV annuity with software like gross margin of 79.6% and operating margin of 33.7%, funding research and development of $5.80B in 2025 and a capital return program that paid $4.00B in cash dividends and repurchased $1.92B of stock in 2025. Revenue was flat at $27.30B in FY2021, $27.28B in FY2022 and $27.12B in FY2023 on an SEC EDGAR basis, then reaccelerated to $28.75B in FY2024 and $29.44B in FY2025, with year over year revenue growth of 10.2% cited in the valuation snapshot. Operating leverage snapped back with it, with SEC EDGAR operating income of $7.61B in FY2023, $1.66B in FY2024 and $10.02B in FY2025, and net income of $5.67B, $480.00M and $8.51B across the same years.

Milestones map directly to that P and L. First, HIV treatment dominance led by Biktarvy, extended by long acting Sunlenca and Yeztugo lenacapavir, including a partnership with Pan American Health Organization to expand lenacapavir for pre exposure prophylaxis across Latin America and the Caribbean. That pits Gilead against GSK majority owned ViiV in treatment and prevention, where adherence and dosing are the moat. Second, hepatitis C with Epclusa, a former growth engine now a cash cow competing with AbbVie. Third, Veklury in COVID-19, episodic but high margin. Fourth, oncology and cell therapy, where Yescarta and Tecartus compete with Novartis and Bristol Myers Squibb in CAR T logistics and Trodelvy competes in antibody drug conjugates against AstraZeneca and Daiichi Sankyo Enhertu and Merck programs. Management highlighted continued strength in HIV, Trodelvy and Livdelzi as drivers of recent base business performance (per investors.gilead.com, August 2026). The balance sheet at FY2025 shows the cost of that diversification, with total assets of $59.02B, cash and cash equivalents of $7.56B, total debt of $24.94B including long term debt of $22.13B, and stockholders equity of $22.70B, supporting operating cash flow of $10.02B.

Ownership And Management Character

Ownership is classic large cap pharma, not insider controlled. Institutions hold 92.11% of shares, 92.21% of float, across 3,122 institutions, while insiders hold about 0.11%. That float, plus a 52 week range of $114.02 to $160.51 and a last close of $159.08 near the $160.51 high, explains the 1 year return of 35.3% and 5 year return of 182.3% from a 5 year low of $48.96. Analysts price that execution at a forward price to earnings ratio of 16.05 and enterprise value to EBITDA of 14.97 on enterprise value of $218.53B, with a mean target of $160.19 and a buy recommendation. Leadership is operator led. Daniel ODay serves as Chairman and Chief Executive Officer, with Andrew Dickinson as Chief Financial Officer, Dietmar Berger as Chief Medical Officer and Johanna Mercier as Chief Commercial and Corporate Affairs Officer (per gilead.com leadership disclosure and investors.gilead.com, August 2026). The character is commercial execution plus disciplined virology reinvestment and external sourcing through collaborations with Merck, Arcus Biosciences, Janssen, Japan Tobacco, Assembly Biosciences, Merus, Terray and LEO Pharma, rather than bet the company M and A.

• HIV moat: Biktarvy plus Descovy plus long acting lenacapavir, defended by adherence, PrEP expansion and payer contracting.
• Beyond HIV: Livdelzi, Trodelvy and cell therapy as the test of whether Gilead can replicate antiviral margins in oncology.
• Holder base: 3,122 institutions at 92.11% ownership reward base business growth and $4.00B dividends, not insider vision.

Business Model & Strategy

Gilead Sciences, headquartered in Foster City, California and incorporated in 1987, is a chronic therapy compounder with 17,000 employees and a $197.25B market capitalization at $159.08 per share. The economic engine is antiretroviral durability: FY2025 revenue of $29.44B produced gross profit of $23.21B at a 79.6% gross margin and operating income of $10.02B, with free cash flow of $9.77B supporting $4.00B in cash dividends paid and $1.92B in share repurchases. That cash funds $5.80B in annual research and development and a balance sheet carrying $24.94B in total debt against $7.56B in cash and cash equivalents.

What it sells and to whom

Gilead sells prescription medicines in the United States, Europe and internationally through wholesalers, specialty pharmacies, physicians and public payers. It reports as one operating unit but commercializes as four franchises:

• HIV: Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca (lenacapavir), Symtuza and Yeztugo (lenacapavir for prevention). This is the core annuity. Second quarter 2026 HIV sales were $5.7B, up 12% year over year, with Biktarvy sales of $3.8B, up 7% (per stocktitan.net, August 2026 and finance.yahoo.com, August 2026).
• Liver disease: Epclusa and Vemlidy for hepatitis C and B, plus Livdelzi (seladelpar) for primary biliary cholangitis. Livdelzi more than doubled year over year in the second quarter of 2026 (per finance.yahoo.com, August 2026).
• Oncology and cell therapy: Trodelvy for intravenous use in solid tumors, plus CAR T therapies Yescarta and Tecartus. Trodelvy grew 26% year over year in the second quarter of 2026 (per finance.yahoo.com, August 2026).
• Other acute and legacy: Veklury for COVID-19 and AmBisome for invasive fungal infection. Veklury is the swing factor, with total second quarter 2026 revenues of $7.8B, up 10%, driven by HIV, Trodelvy and Livdelzi and partly offset by lower Veklury, cell therapy and hepatitis C sales (per sec.gov Q2 2026 results summary, August 2026).

Recurring versus one time revenue

HIV treatment is the definition of recurring revenue. Once daily Biktarvy creates multi year adherence, high switching costs and payer formulary lock, in contrast to ViiV Healthcare, the GSK and Pfizer joint venture, which competes with dolutegravir and long acting cabotegravir. Prevention is now the second recurring leg. Quarterly PrEP sales doubled year over year to exceed $1B for the first time, a $4B annual run rate (per finance.yahoo.com, August 2026), led by Descovy and Yeztugo, the twice yearly lenacapavir injection. Management lifted full year HIV growth guidance to 9% to 10% from 8% on that strength (per finance.yahoo.com, August 2026). Hepatitis C, by contrast, is curative and depleting. Harvoni and Epclusa cured the warehoused pool, so revenue decays by definition. Veklury is episodic pandemic inventory, guided to only about $300M in product sales for full year 2026 (per stocktitan.net, August 2026). Cell therapy is lumpy, hospital administered and competes directly with Bristol Myers Squibb Breyanzi, while Trodelvy competes in antibody drug conjugates against AstraZeneca and Daiichi Sankyo Enhertu on cycles of therapy, not lifetime daily dosing.

Strategy and competitive flywheel

The strategy is to extend HIV duration from daily pill to long acting injection to weekly oral, then redeploy the 33.7% operating margin into oncology, liver and virology options. Lenacapavir is the platform. After the twice yearly PrEP approval, the FDA accepted a supplemental application for once weekly oral Yeztugo 300-mg for PrEP with a target action date of February 2, 2027 (per investors.gilead.com, June 2026 and pharmaphorum.com, October 2026). Phase 3 ISLEND-1 and ISLEND-2 data presented in 2026 support a filing for weekly oral islatravir plus lenacapavir in 2027 in collaboration with Merck (per finance.yahoo.com, August 2026). That directly answers ViiV Apretude and Merck weekly ambitions by owning both injectable and oral long acting PrEP. Commercial scale funds access and deal flow. Gilead expanded no profit supply with PEPFAR and the Global Fund toward up to 3 million people through 2028 and signed royalty free licenses covering 120 countries (per investors.gilead.com, July 2026). The same playbook drives partnerships with Arcus Biosciences, Merck Sharp and Dohme, Janssen, Japan Tobacco, Assembly Biosciences, Merus for trispecific antibodies, Terray Therapeutics and LEO Pharma for oral STAT6, plus a Pan American Health Organization partnership for lenacapavir PrEP in Latin America and the Caribbean. Win HIV adherence, convert prevention to twice yearly dosing, harvest $10.02B in operating income to buy the next oncology leg, repeat.

Segments & Products

Gilead is an HIV annuity trying to buy a second act in prevention and oncology. SEC EDGAR puts 2025 revenue at $29.44B, up from $28.75B in 2024 and $27.12B in 2023 after two flat years at $27.28B in 2022 and $27.30B in 2021. That scale, on 17,000 employees and a $197.25B market cap at $159.08, still rests on daily oral HIV regimens sold in the United States, Europe and internationally, plus a newer long acting prevention franchise and a smaller, more competitive oncology and cell therapy book.

HIV treatment remains the compounder. Biktarvy is the single tablet anchor against ViiV Healthcare regimens like Dovato, Juluca and long acting Cabenuva, and against Merck and Johnson and Johnson combinations. Gilead does not disclose full year mix in the pack, but second quarter 2026 HIV sales were $5.7B, up 12% year over year, with Biktarvy at $3.8B, up 7% (per sec.gov, August 2026). Management cited higher average realized price, favorable inventory and higher demand for Biktarvy, and higher average realized price and demand for HIV overall (per sec.gov, August 2026). Sequentially HIV sales rose 13% on inventory build (per finance.yahoo.com, August 2026). That pricing commentary matters because U.S. HIV pricing, 340B and Medicaid mix, and ViiV switching pressure are the perennial bear case.

PrEP is now the growth leg. Quarterly PrEP sales exceeded $1B for the first time in the second quarter of 2026, doubling year over year, implying a $4B annual run rate (per finance.yahoo.com, August 2026). The driver is Yeztugo, or lenacapavir, approved June 18, 2025 as the first twice yearly injectable PrEP option after PURPOSE 1 and PURPOSE 2 showed at least 99.9% of participants remained HIV negative (per gilead.com, June 2025). That pits a twice yearly injection against daily Descovy and Truvada generics and ViiV's every two month Apretude, where adherence and clinic capacity decide share. Gilead is extending the moat to convenience: FDA accepted a supplemental application for Yeztugo 300-mg tablets as a once weekly oral PrEP option with a February 2, 2027 action date (per investors.gilead.com, June 2026), and reported positive Phase 3 ISLEND-1 and ISLEND-2 data for once weekly islatravir plus lenacapavir with Merck as a potential weekly treatment switch from Biktarvy (per gilead.com, August 2026). The company also points to a PAHO partnership to push lenacapavir PrEP across Latin America and the Caribbean, a low price but high volume access market.

Liver, COVID and oncology fill out the base. Epclusa and Vemlidy are mature HCV and HBV cash contributors in a market largely cured and now contested by AbbVie Mavyret, while Livdelzi in primary biliary cholangitis, alongside Trodelvy in oncology, helped lift non Veklury product sales to $7.6B in the quarter, up 10% (per finance.yahoo.com, August 2026). Veklury is the swing COVID hospital product, structurally declining. In oncology, Trodelvy, an antibody drug conjugate, competes with AstraZeneca and Daiichi Sankyo Enhertu and chemotherapy in solid tumors, while Yescarta and Tecartus CAR T therapies compete with Bristol Myers Squibb Breyanzi and Abecma and Novartis Kymriah for relapsed lymphoma, where manufacturing slots and payer authorization cap growth compared with a pill.

Pricing power and what funds the pivot. Gross margin was 79.6% with operating margin at 33.7%, classic patented antiviral economics on chronic therapy and concentrated payers. SEC EDGAR operating income rebounded to $10.02B in 2025 from $1.66B in 2024, net income to $8.51B from $480.00M, supporting $10.02B in operating cash flow and $9.46B in free cash flow against $5.80B of research and development. Management raised full year HIV growth guidance to 9% to 10% from 8% and guided 2026 product sales excluding Veklury to $29.8B to $30.1B (per zacks.com, October 2026). The underwrite is simple: defend Biktarvy price and share, convert daily PrEP to twice yearly Yeztugo and then weekly oral, and use the cash to make Trodelvy, Livdelzi and cell therapy matter before HIV patent pressure builds.

Operations & Go-to-Market

Gilead Sciences operates as a fully integrated biopharma seller, not a discovery boutique. It discovers, develops and commercializes its own medicines from Foster City, California, where it has been headquartered since its incorporation in 1987, and it sells in the United States, Europe and internationally with 17,000 employees supporting $29.44B in FY2025 revenue. That revenue density, roughly $1.73M per employee on a headcount basis, plus a 79.6% gross margin and 33.7% operating margin, is the signature of an oral small molecule engine layered with higher touch injectables and cell therapy.

Manufacturing and delivery footprint

Gilead does not disclose site level capacity in the pack, but the product mix defines the delivery footprint. The core is oral, pharmacy dispensed HIV and liver disease therapy built for scale. The pointed end is clinic administered therapy that requires cold chain, infusion capacity and certified sites.

• High volume oral: Biktarvy, Genvoya, Odefsey, Descovy, Symtuza, Epclusa and Vemlidy, dispensed through retail and specialty pharmacy and adherence driven.
• Provider administered: Trodelvy for intravenous use, Sunlenca and Yeztugo in HIV, AmBisome for severe fungal infection and Veklury for COVID-19, all hospital or infusion centered.
• Patient specific cell therapy: Yescarta as a suspension for intravenous infusion and Tecartus as a T cell therapy for adult patients, which by definition runs through a limited network of authorized treatment centers, apheresis logistics and tight scheduling.

Distribution and sales model

The commercial model is specialist led and payer intensive, with HIV treatment as the recurring base, HIV prevention as pre exposure prophylaxis as the growth wedge, and oncology and liver as the diversification call. Recent commercial cadence confirms the mix. Total second quarter 2026 revenue reached $7.8B, up 10% year over year, led by HIV, Trodelvy and Livdelzi (per investors.gilead.com, August 2026). HIV sales were $5.7B, up 12%, with product sales excluding Veklury at $7.6B, up 10% (per finance.yahoo.com, August 2026). Trodelvy was singled out as up 26% year over year on demand in triple negative and pre treated HR positive, HER2 negative metastatic breast cancer (per finance.yahoo.com, August 2026).

Vertical integration and partnerships

Gilead keeps discovery, development and commercialization in house, funding it with $5.80B of research and development in FY2025 against $29.44B of revenue, but it buys optionality aggressively. Named collaborators include Arcus Biosciences, Merck Sharp and Dohme Corp. and Merck and Co., Janssen Sciences Ireland, Japan Tobacco, Everest Medicines, Assembly Biosciences and Tentarix Biotherapeutics, plus Shenzhen Pregene Biopharma and Abingworth. Platform deals add Merus N.V. for dual tumor associated antigen targeting trispecific antibodies, Terray Therapeutics for small molecule discovery and LEO Pharma for the oral STAT6 program. It is a classic integrated buyer model: own the HIV cash engine, rent early innovation.

Geographic exposure

The United States remains the pricing and adherence anchor, Europe provides the second reimbursed leg, and the rest of world is access and volume. The most explicit access operation is the partnership with the Pan American Health Organization to accelerate lenacapavir for HIV prevention as pre exposure prophylaxis across all PAHO member states in Latin America and the Caribbean. Operationally that matters because prevention broadens the buyer from the individual prescriber to governments, NGOs and multilateral tenders, a different contracting muscle than U.S. commercial HIV. For investors, the read is clean: a Foster City controlled supply and regulatory core, a U.S. and Europe monetization core, and a partnered global health channel that extends the HIV franchise without adding 17,000 headcount density.

Financials

Gilead is a slow top line, violent bottom line story. Revenue was essentially flat for three years, then broke out, with SEC EDGAR revenue of $27.30B in FY2021, $27.28B in FY2022, $27.12B in FY2023, $28.75B in FY2024 and $29.44B in FY2025. That is a two year acceleration from stagnation to growth, consistent with yfinance revenue growth of 10.2%. The mix matters more than the slope. HIV, led by Biktarvy, Descovy, Sunlenca and now Yeztugo, funds everything else, while Trodelvy, Livdelzi, cell therapy from Yescarta and Tecartus, plus Veklury and AmBisome, determine whether Gilead grows like a specialty innovator or mills around like a legacy antiviral seller competing against ViiV, Merck and generic Truvada pressure. The latest commercial pulse was strong, with second quarter 2026 revenues up 10% to $7.8B led by HIV, Trodelvy and Livdelzi, per investors.gilead.com, Aug 2026, and management lifting base business expectations on 12% HIV growth.

Profitability is elite at the gross line, lumpy at the net line. Yfinance screens gross margin at 79.6% and operating margin at 33.7%, the classic Gilead fingerprint of a high priced oral and injectable portfolio with minimal cost of goods. Below that, history is acquisition and impairment noise. EDGAR operating income was $9.92B in FY2021, $7.33B in FY2022, $7.61B in FY2023, $1.66B in FY2024 and $10.02B in FY2025, while EDGAR net income swung from $6.22B in FY2021 to $4.59B in FY2022 to $5.67B in FY2023 to $480.00M in FY2024 and then to $8.51B in FY2025. Yfinance EBITDA tells the same snapback, $8.85B in 2022, $10.50B in 2023, $4.43B in 2024 and $13.58B in 2025. Diluted EPS tracked it, at $3.64 in 2022, $4.50 in 2023, $0.38 in 2024 and $6.78 in 2025, all yfinance. Yfinance currently shows profit margin at -10.6%, ROE at -20.7% and ROA at 14.1%, a trailing screen artifact that contrasts with FY2025 reported profit of $8.51B in EDGAR and underscores why investors must use full year EDGAR income, not trailing ratios, for Gilead. R and D discipline held through the cycle, with yfinance R and D of $4.98B in 2022, $5.72B in 2023, $5.91B in 2024 and $5.80B in 2025.

Balance sheet: levered, but covered

Gilead runs a big pharma balance sheet, not a biotech balance sheet. Total assets were $63.17B in FY2022, $62.12B in FY2023, $58.99B in FY2024 and $59.02B in FY2025 per EDGAR. Cash was $5.41B in 2022, $6.08B in 2023, $9.99B in 2024 and $7.56B in 2025 per yfinance, against total debt of $25.23B in 2022, $24.99B in 2023, $26.71B in 2024 and $24.94B in 2025, with long term debt of $22.13B in 2025, all yfinance. Net debt is therefore roughly $17.38B on 2025 cash versus total debt, leaving enterprise value at $218.53B on a $197.25B market cap at $159.08 per share, all yfinance. Equity was $21.24B in 2022, $22.83B in 2023, $19.33B in 2024 and $22.70B in 2025 per EDGAR, so leverage is real at over 1.0 times debt to equity, but assets and cash generation dwarf maturities in a way that supports the dividend. The stock sits at $159.08, just under the $160.51 52 week high and well above the $114.02 low, with a $160.19 mean target, forward P/E of 16.05 and EV/EBITDA of 14.97, all yfinance.

Cash flow and capital return

Cash conversion is the bull case. Operating cash flow was $9.07B in 2022, $8.01B in 2023, $10.83B in 2024 and $10.02B in 2025 per yfinance, with free cash flow of $8.34B, $7.42B, $10.30B and $9.46B across the same years, versus a $9.77B trailing free cash flow screen, all yfinance. Capex is trivial at $728.00M in 2022, $585.00M in 2023, $523.00M in 2024 and $563.00M in 2025, all yfinance, which is why almost every incremental HIV dollar drops to holders. Capital return is dividends first, buybacks second. Cash dividends paid were $3.71B in 2022, $3.81B in 2023, $3.92B in 2024 and $4.00B in 2025, while repurchases were $1.40B, $1.00B, $1.15B and $1.92B, all yfinance. That $5.92B combined 2025 return was fully covered by $9.46B in free cash flow. Forward, the debate is Yeztugo PrEP durability and Trodelvy oncology share versus GSK, Gilead noted Yeztugo momentum and FDA acceptance of a once weekly oral PrEP filing with a Feb. 2, 2027 action date, per investors.gilead.com, June 2026, which, if executed, protects the HIV annuity that funds the payout.

Competitive Landscape & Moat

Gilead Sciences at $159.08, a $197.25B market capitalization and $218.53B enterprise value, is a scale HIV franchise with selective oncology, cell therapy and liver assets attached. FY2025 revenue was $29.44B under SEC XBRL, up from $28.75B in FY2024 and $27.12B in FY2023, with $23.21B in gross profit at 79.6% gross margin and 33.7% operating margin. That economics funds $5.80B in annual R and D, $10.02B in SEC operating income and $8.51B in net income, or $6.78 in diluted EPS, after only $480.00M in net income in FY2024. The balance sheet carries $59.02B in assets against $24.94B in total debt, including $22.13B long term, and $7.56B in cash, while FY2025 operating cash flow was $10.02B, free cash flow was $9.46B, dividends paid were $4.00B and buybacks were $1.92B. Momentum remains HIV led. Total second quarter 2026 revenues rose 10% to $7.8B and product sales excluding Veklury rose 10% to $7.6B, driven by HIV, Trodelvy and Livdelzi (per gilead.com, August 2026).

HIV: Gilead leads, ViiV chases the dosing interval

The core contest is Gilead versus ViiV Healthcare, the GSK majority joint venture with Shionogi and Pfizer, plus Johnson and Johnson and Merck and Co. Gilead fields Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza and Yeztugo lenacapavir for HIV treatment and prevention. ViiV counters with dolutegravir based regimens, the cabotegravir plus rilpivirine injectables Cabenuva for treatment and Apretude for PrEP developed with Johnson and Johnson, and fostemsavir Rukobia for multidrug resistant disease. Merck Sharp and Dohme Corp., a named Gilead collaborator, is simultaneously a rival with islatravir and doravirine efforts. Gilead is winning the current interval shift. Second quarter HIV sales were $5.7B, up 12% year over year on Biktarvy, Descovy and Yeztugo (per finance.yahoo.com, August 2026). Quarterly PrEP sales doubled year over year to exceed $1B for the first time, with Yeztugo described as the leading long acting PrEP option for new patient starts (per finance.yahoo.com, August 2026). Yeztugo itself did $232M in the quarter, up 40% sequentially, targeting approximately $1B in full year 2026 sales (per finance.yahoo.com, August 2026). ViiV retains structural scale, with GSK retaining a 78.3% stake and Shionogi holding 21.7% after Pfizer exited (per pharmaphorum.com, October 2026), but Gilead's twice yearly lenacapavir injection plus a planned once weekly oral islatravir plus lenacapavir filing in 2027 sets the cadence ViiV must match.

Outside HIV: cash cow, challenger, laggard

In hepatitis C and B, Epclusa, Vemlidy and Vosevi face AbbVie Mavyret and low priced generics in a shrinking treated pool, a harvest business, not a growth engine. In liver disease, Livdelzi seladelpar for primary biliary cholangitis competes with Intercept and generic ursodiol era pricing, but adds a rare disease price point. In oncology, Trodelvy sacituzumab govitecan is a credible challenger in Trop-2 antibody drug conjugates against AstraZeneca plus Daiichi Sankyo Dato-DXd and Roche legacy chemotherapy franchises, without the lung and breast dominance of those houses. In cell therapy, Yescarta and Tecartus face Bristol Myers Squibb Breyanzi and Abecma, Novartis Kymriah, and Johnson and Johnson plus Legend Carvykti, where manufacturing slots, cytokine release management and outpatient logistics matter more than list price. Veklury remdesivir and AmBisome are hospital installed base products structurally pressured by Pfizer Paxlovid and generic antifungals. Gilead lags where infusion center scale, solid tumor commercial muscle or autologous manufacturing scale decide share.

Moat: adherence, prescriber habit, patents and procurement

• Switching costs and resistance risk: stable HIV patients and physicians avoid switching suppressive regimens. That protects Biktarvy and Descovy and makes long acting lenacapavir an upsell within Gilead, not a rip out.
• Scale and R and D compounding: $29.44B in revenue, $5.80B in R and D and collaborations with Arcus, Merus for trispecific antibodies, Terray, LEO Pharma on oral STAT6, Assembly, Tentarix and Everest sustain combination and long acting pipelines rivals cannot replicate physician by physician.
• Installed base and brand: 17,000 employees support payer, 340B, clinic and PAHO procurement channels, including a partnership with Pan American Health Organization to accelerate lenacapavir PrEP access across Latin America and the Caribbean.
• Regulation as barrier: twice yearly dosing, weekly oral filings, PrEP guidelines and patent estates on tenofovir prodrugs and capsid inhibition extend duration. FDA acceptance of once weekly oral lenacapavir for PrEP review, with decision timing cited for February, shows the regulatory flywheel (per finance.yahoo.com, August 2026).

At 16.05 times forward earnings and 14.97 times EV to EBITDA, with a $160.19 mean target against $159.08 and a $160.51 52 week high versus $114.02 low, the market prices HIV durability plus lenacapavir optionality and discounts oncology. The moat is narrow but real: adherence driven retention, guideline embedded prescribing and dosing convenience, defended by $9.46B in free cash flow and $7.56B in cash against $24.94B in debt. It breaks if ViiV or Merck delivers a longer, safer or cheaper interval, if Trodelvy stalls against Dato-DXd, or if cell therapy utilization keeps sliding.

Key Risks

• 1. HIV concentration: revenue of $29.44B in FY2025 lives or dies on Biktarvy, Descovy and follow ons including Sunlenca and Yeztugo.
• 2. Pricing power at risk: a 79.6% gross margin and 33.7% operating margin model is exposed to payers, 340B, and government negotiation.
• 3. Oncology and cell therapy fail to diversify: Trodelvy, Yescarta and Tecartus must prove durable growth against entrenched Merck, AstraZeneca, GSK and Novartis franchises.
• 4. Levered balance sheet with rigid payouts: $24.94B of total debt and $22.13B of long term debt against $7.56B of cash plus $4.00B of annual dividends.
• 5. Lumpy R and D and deal led earnings: net income swung from $480.00M in FY2024 to $8.51B in FY2025, a profile the $159.08 price and 16.05 forward P and E do not forgive.

1. The company is an HIV company with side businesses

Gilead discloses Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza and Yeztugo for HIV-1 alongside Epclusa, Vemlidy, AmBisome and Veklury, but commercial momentum remains HIV led, with management crediting the HIV portfolio plus Trodelvy and Livdelzi for base business strength and raising base business expectations (per sec.gov, August 2026). That matters because FY2025 revenue was $29.44B and yoy revenue growth was 10.2%, so any Biktarvy share loss, Descovy generic or payer shift, or slower uptake of twice yearly lenacapavir for PrEP and the weekly oral islatravir plus lenacapavir program discussed toward potential filing (per investors.gilead.com, August 2026) hits the whole $197.25B market cap thesis. Competitors are not theoretical: GSK through ViiV, Janssen and Merck sell competing HIV regimens and long actings, and prevention adds GSK's Apretude pressure plus public health and generic access programs such as the PAHO partnership to expand lenacapavir access across Latin America and the Caribbean (per investors.gilead.com, September 2026).

What would confirm this risk: flattening HIV treatment volume while prevention growth relies on discounting or volume guarantees rather than full price conversion.

2. Price, payer and policy leverage against a high margin annuity

Gilead prints 79.6% gross margin and 33.7% operating margin on $23.21B of 2025 gross profit and $10.02B of operating income, margins that assume sustained U.S. HIV pricing, favorable formulary placement, and limited 340B and Medicaid drag. The bear case is that scale invites scrutiny: HIV and hepatitis portfolios are core to federal and state programs, Veklury showed how quickly a $29.44B revenue base can face utilization cliffs, and any Inflation Reduction Act, 340B, or state Medicaid action that compresses net price flows directly to a model with $5.80B of R and D and 17000 employees to support. Unlike diversified Merck, Johnson and Johnson or Pfizer, Gilead lacks a broad non virology cushion to offset a 200 to 300 basis point net price reset.

What would confirm this risk: gross margin compression alongside management commentary on higher rebates, 340B mix, or payer restrictions on HIV or Livdelzi.

3. Trodelvy and cell therapy must earn their place in oncology

Beyond virology, Gilead lists Trodelvy for intravenous use plus Yescarta and Tecartus cell therapies, areas where commercial execution has been uneven and competition is brutal from Merck's Keytruda, AstraZeneca and Daiichi's Enhertu, GSK and Roche in breast and lung, and Novartis, Bristol Myers and Janssen in cell therapy and lymphoma. FY2025 EBITDA was $13.58B versus $4.43B in 2024 and operating cash flow was $10.02B, but oncology and cell therapy revenue has not yet de risked the HIV concentration, leaving Gilead paying full oncology SG and A and manufacturing cost without Big Pharma oncology scale. Clinical or manufacturing setbacks, safety signals, or share loss to antibody drug conjugate rivals would strand investment and force more deals.

What would confirm this risk: sequential declines in cell therapy or HCV combined with Trodelvy growth that trails rival antibody drug conjugate launches despite higher spend.

4. Debt plus dividend leaves little room for a miss

The balance sheet carries $24.94B of total debt, $22.13B of long term debt and $36.41B of total liabilities against $59.02B of assets, $22.70B of equity and $7.56B of cash, which is why enterprise value of $218.53B sits $21.28B above the $197.25B market cap. Capital return is sticky: $4.00B of cash dividends paid plus $1.92B of stock repurchases in 2025 against $10.02B of operating cash flow and $9.46B of free cash flow, or $9.77B on a trailing basis, plus only $563.00M of capital expenditure. That is comfortable when HIV grows 9% to 10% and the stock trades at $159.08 near the $160.51 52 week high and $160.19 target, but it turns pro cyclical if revenue stalls, with holders crowded by 3122 institutions owning 92.11% of shares and limited insider ownership to buffer volatility from $114.02 to $159.08 over the past year.

What would confirm this risk: debt refinanced at higher coupons while the dividend and buyback are maintained despite falling operating cash flow.

5. Earnings quality depends on deals, litigation and one time items

SEC XBRL facts show net income of $6.22B in FY2021, $4.59B in FY2022, $5.67B in FY2023, $480.00M in FY2024 and $8.51B in FY2025, with operating income of $9.92B, $7.33B, $7.61B, $1.66B and $10.02B over the same period and diluted EPS of $6.78 in 2025 versus $0.38 in 2024. That 2024 collapse and 2025 snapback, mirrored in EBITDA from $10.50B to $4.43B to $13.58B, reflects impairments, deal and legal charges and other nonrecurring items more than unit demand, producing negative 10.6% profit margin on a trailing basis, negative 20.7% ROE versus 14.1% ROA, and an EV to EBITDA multiple of 14.97 that looks reasonable only if $8.51B is repeatable. Gilead lists collaborations with Arcus, Merck, Janssen, Japan Tobacco, Assembly, Merus, Terray and LEO Pharma, a roster that can extend HIV and oncology but also concentrates binary readouts and upfront economics in partners hands.

What would confirm this risk: another year where GAAP net income diverges by billions from operating cash flow on impairments or deal charges while R and D stays near $5.80B without a wholly owned blockbuster launch.

Lessons

Gilead Sciences at $159.08, valued at $197.25B with an enterprise value of $218.53B, is a case study in how a single durable franchise funds a $29.44B FY2025 revenue company, per SEC EDGAR XBRL facts, through cycles that break GAAP optics. The HIV system of Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza and Yeztugo, plus Epclusa, Vemlidy, Yescarta, Tecartus, Trodelvy, AmBisome and Veklury, shows four transferable rules.

1. An annuity franchise pays for everything else

Gilead posts 79.6% gross margin on $29.44B in FY2025 revenue, with operating income of $10.02B in FY2025 XBRL facts. That margin structure, built on HIV treatment where switching costs and adherence favor incumbents like Biktarvy and Descovy over newer oncology assets like Trodelvy and Yescarta, sustains $5.80B of research and development in 2025 and $10.02B of operating cash flow. The lesson: in biopharma, unlike in low margin generics, one protected annuity can carry a full pipeline and a dividend.

2. Ignore single year GAAP, underwrite cash

Net income was $480.00M in FY2024 then $8.51B in FY2025, diluted EPS moved from $0.38 to $6.78, and EBITDA moved from $4.43B to $13.58B. Operating cash flow did not move that way, at $10.83B in 2024 and $10.02B in 2025, with free cash flow at $10.30B then $9.46B. Yfinance still screens the stock with a profit margin of -10.6% and ROE of -20.7% against ROA of 14.1%, a reminder that trailing screens lag the XBRL cycle. The lesson: price mature drug makers on sustained operating cash flow and $9.77B scale free cash flow, not on the impairment or deal year.

3. Maturity is a capital allocation business

Gilead carries $24.94B of total debt, including $22.13B of long term debt, against $22.70B of stockholders equity and $59.02B of total assets, with $7.56B of cash and cash equivalents. In 2025 it paid $4.00B in cash dividends and repurchased $1.92B of capital stock from $10.02B of operating cash flow, while the market prices it at 16.05 times forward earnings and 14.97 times EV to EBITDA, with an analyst target mean of $160.19 versus $159.08 and a 52 week range of $114.02 to $160.51. The lesson: when revenue growth was 10.2% year over year but the 1 year return was 35.3% and the 5 year return was 182.3%, the compounding came from steady harvesting and return of cash, not from reinventing the balance sheet.

• Externalize the pipeline: Gilead lists collaborations with Merck Sharp and Dohme Corp., Janssen Sciences Ireland, Arcus Biosciences, Merus N.V., Assembly Biosciences, Tentarix Biotherapeutics, Terray Therapeutics and LEO Pharma, plus the PAHO partnership for lenacapavir PrEP. With 17000 employees and institutions holding 92.108% of shares across 3122 institutions, the model is to buy and share optionality rather than to invent every modality in house.
• Compare within the portfolio: judge HIV durability separately from Cell Therapy and Trodelvy oncology volatility and from Veklury cyclicality, because cash conversion and patent risk differ completely by franchise.